Exxel Pharma is focused on

  • Commercialization of its FAAH inhibitor drugs and providing innovative medicines to current, unmet medical needs.
  • Positioning URB937 as a novel treatment for chronic cough and a safe, non-addictive alternative to opioid drugs for pain management.
  • Expanding the Company’s drug pipeline with follow-on molecules, and maximizing the value of the Company’s IP portfolio.
  • Achieving the goal of providing optimal returns for our investors.


Exxel Pharma to Participate in the Virtual Investor Summer Spotlight Series

Live moderated video webcast with members of the Exxel Pharma Leadership Team on Tuesday, July 11th 1:00 PM ET